These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 27115831)

  • 21. Discovery of Novel Disruptor of Silencing Telomeric 1-Like (DOT1L) Inhibitors using a Target-Specific Scoring Function for the (S)-Adenosyl-l-methionine (SAM)-Dependent Methyltransferase Family.
    Wang Y; Li L; Zhang B; Xing J; Chen S; Wan W; Song Y; Jiang H; Jiang H; Luo C; Zheng M
    J Med Chem; 2017 Mar; 60(5):2026-2036. PubMed ID: 28165739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library.
    Gibbons GS; Chakraborty A; Grigsby SM; Umeano AC; Liao C; Moukha-Chafiq O; Pathak V; Mathew B; Lee YT; Dou Y; Schürer SC; Reynolds RC; Snowden TS; Nikolovska-Coleska Z
    Eur J Med Chem; 2020 Mar; 189():112023. PubMed ID: 31978781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The application of small molecule bioactive probes in the identification of cellular targets].
    Zhang J; Zhou HC
    Yao Xue Xue Bao; 2012 Mar; 47(3):299-306. PubMed ID: 22645752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virtual screening and biological evaluation of novel small molecular inhibitors against protein arginine methyltransferase 1 (PRMT1).
    Xie Y; Zhou R; Lian F; Liu Y; Chen L; Shi Z; Zhang N; Zheng M; Shen B; Jiang H; Liang Z; Luo C
    Org Biomol Chem; 2014 Dec; 12(47):9665-73. PubMed ID: 25348815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective inhibitors of protein methyltransferases.
    Kaniskan HÜ; Konze KD; Jin J
    J Med Chem; 2015 Feb; 58(4):1596-629. PubMed ID: 25406853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Developing new chemical tools for DNA methyltransferase 1 (DNMT 1): a small-molecule activity-based probe and novel tetrazole-containing inhibitors.
    Zhu B; Ge J; Yao SQ
    Bioorg Med Chem; 2015 Jun; 23(12):2917-27. PubMed ID: 25801160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small molecule probe suitable for in situ profiling and inhibition of protein disulfide isomerase.
    Ge J; Zhang CJ; Li L; Chong LM; Wu X; Hao P; Sze SK; Yao SQ
    ACS Chem Biol; 2013 Nov; 8(11):2577-85. PubMed ID: 24070012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DOT1L Activity Promotes Proliferation and Protects Cortical Neural Stem Cells from Activation of ATF4-DDIT3-Mediated ER Stress In Vitro.
    Roidl D; Hellbach N; Bovio PP; Villarreal A; Heidrich S; Nestel S; Grüning BA; Boenisch U; Vogel T
    Stem Cells; 2016 Jan; 34(1):233-45. PubMed ID: 26299268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes.
    Shi H; Zhang CJ; Chen GY; Yao SQ
    J Am Chem Soc; 2012 Feb; 134(6):3001-14. PubMed ID: 22242683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development.
    Rogawski DS; Grembecka J; Cierpicki T
    Future Med Chem; 2016 Sep; 8(13):1589-607. PubMed ID: 27548565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
    Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
    Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Public resources for chemical probes: the journey so far and the road ahead.
    Antolin AA; Workman P; Al-Lazikani B
    Future Med Chem; 2021 Apr; 13(8):731-747. PubMed ID: 31778323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of Small Molecule Inhibitors of Human As(III) S-Adenosylmethionine Methyltransferase (AS3MT).
    Dong H; Madegowda M; Nefzi A; Houghten RA; Giulianotti MA; Rosen BP
    Chem Res Toxicol; 2015 Dec; 28(12):2419-25. PubMed ID: 26577531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disruptor of telomeric silencing 1-like (DOT1L): disclosing a new class of non-nucleoside inhibitors by means of ligand-based and structure-based approaches.
    Sabatino M; Rotili D; Patsilinakos A; Forgione M; Tomaselli D; Alby F; Arimondo PB; Mai A; Ragno R
    J Comput Aided Mol Des; 2018 Mar; 32(3):435-458. PubMed ID: 29335872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat.
    Kuntz KW; Campbell JE; Keilhack H; Pollock RM; Knutson SK; Porter-Scott M; Richon VM; Sneeringer CJ; Wigle TJ; Allain CJ; Majer CR; Moyer MP; Copeland RA; Chesworth R
    J Med Chem; 2016 Feb; 59(4):1556-64. PubMed ID: 26769278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteome profiling reveals potential cellular targets of staurosporine using a clickable cell-permeable probe.
    Shi H; Cheng X; Sze SK; Yao SQ
    Chem Commun (Camb); 2011 Oct; 47(40):11306-8. PubMed ID: 21922114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of the DOT1L network: implications of diverse roles for DOT1L.
    Park G; Gong Z; Chen J; Kim JE
    Protein J; 2010 Apr; 29(3):213-23. PubMed ID: 20431927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimization of High-Throughput Methyltransferase Assays for the Discovery of Small Molecule Inhibitors.
    Dong G; Yasgar A; Peterson DL; Zakharov A; Talley D; Cheng KC; Jadhav A; Simeonov A; Huang R
    ACS Comb Sci; 2020 Aug; 22(8):422-432. PubMed ID: 32525297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: current trends.
    Fabini E; Manoni E; Ferroni C; Rio AD; Bartolini M
    Future Med Chem; 2019 Apr; 11(8):901-921. PubMed ID: 30998113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity-based proteome profiling of potential cellular targets of Orlistat--an FDA-approved drug with anti-tumor activities.
    Yang PY; Liu K; Ngai MH; Lear MJ; Wenk MR; Yao SQ
    J Am Chem Soc; 2010 Jan; 132(2):656-66. PubMed ID: 20028024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.